{
    "clinical_study": {
        "@rank": "137943", 
        "acronym": "PREDICT", 
        "arm_group": {
            "arm_group_label": "Advanced soft tissue sarcoma patients", 
            "description": "Advanced soft tissue sarcoma patients, who have an indication for pazopanib treatment."
        }, 
        "biospec_descr": {
            "textblock": "whole blood"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "This study is a phase IV post registration prospective observational feasibility study in\n      patients with metastatic soft tissue sarcoma. Pazopanib is the registered treatment for\n      patients with advanced soft tissue sarcoma after chemotherapy with doxorubicin or\n      ifosfamide.\n\n        -  This study looks at the possibility of using 18F-2-fluoro-2-deoxy-D-glucose\n           fluorodeoxyglucose (FDG) positron emission tomography PET scans as an early biomarker\n           of pazopanib treatment effect in patients.\n\n        -  It also studies pazopanib pharmacokinetics to see if there are differences between\n           elderly and younger patients.\n\n      The primary objectives are:\n\n        -  To evaluate whether early metabolic response is correlated to clinical benefit.\n\n        -  To evaluate the effect of age (\u2265 70 years) on pazopanib pharmacokinetics.\n\n      The secondary objectives are:\n\n        -  To evaluate whether early metabolic response (% decrease in FDG uptake due to pazopanib\n           therapy) is correlated with pazopanib exposure.\n\n        -  To evaluate whether early metabolic response (% decrease in FDG uptake due to pazopanib\n           therapy) is correlated with the histological subtypes."
        }, 
        "brief_title": "Individualizing Pazopanib Therapy by exploRing the Role of Early Metabolic responsE and Drug Exposure as a preDICTor for Treatment Outcome in Patients With STS", 
        "condition": "Sarcoma, Soft Tissue", 
        "condition_browse": {
            "mesh_term": "Sarcoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subjects must provide written informed consent prior to performance of study-specific\n             procedures or assessments and must be willing to comply with treatment and follow-up.\n\n          2. Age \u2265 18 years. Patients aged 66-69 are eligible for the imaging arm of the study,\n             however they are excluded from the assessment of altered pharmacokinetic behavior in\n             elderly.\n\n          3. Histological confirmed diagnosis of selective subtypes of advanced soft tissue\n             sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have\n             progressed within 12 months after (neo) adjuvant therapy. The following subtypes are\n             eligible:\n\n             Fibroblastic, so-called fibrohistiocytic, leiomyosarcoma, malignant glomus tumours,\n             skeletal muscles, vascular, uncertain differentiation. The following subtypes are NOT\n             eligible: Adipocytic sarcoma (all subtypes), all rhabdomyosarcoma that were not\n             alveolar or pleomorphic, chondrosarcoma, osteosarcoma, Ewing tumours/primitive\n             neuroectodermal tumor, GIST, dermatofibrosarcoma protuberance, inflammatory\n             myofibroblastic sarcoma, malignant mesothelioma and mixed mesodermal tumours of the\n             uterus.\n\n          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n\n          5. Measurable disease criteria (RECIST 1.1).\n\n          6. No radio-, chemo- or tumor specific targeted therapy within the last 4 weeks prior to\n             study entry.\n\n          7. Adequate organ system function as defined in the research protocol.\n\n          8. Minimal evaluable lesion of \u2265 15mm.\n\n        Exclusion Criteria:\n\n          1. Prior malignancy.\n\n          2. Central nervous system (CNS) metastases at baseline, with the exception of those\n             subjects who have previously-treated CNS metastases and who meet both of the\n             following criteria: a) are asymptomatic and b) have no requirement for steroids or\n             enzyme-inducing anticonvulsants in prior 6 months time interval.\n\n          3. Clinically significant gastrointestinal abnormalities that may increase the risk for\n             gastrointestinal bleeding including.\n\n          4. Clinically significant gastrointestinal abnormalities that may affect absorption of\n             investigational product including.\n\n          5. Corrected QT interval (QTc) > 480msecs.\n\n          6. History of any one or more of the following cardiovascular conditions within the past\n             6 months:\n\n               -  Cardiac angioplasty or stenting\n\n               -  Myocardial infarction\n\n               -  Unstable angina\n\n               -  Coronary artery bypass graft surgery\n\n               -  Symptomatic peripheral vascular disease\n\n               -  Class III or IV congestive heart failure, as defined by the New York Heart\n                  Association (NYHA)\n\n          7. Poorly controlled hypertension\n\n          8. History of cerebrovascular accident including transient ischemic attack (TIA),\n             pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6\n             months.\n\n          9. Major surgery or trauma within 28 days prior to first dose of investigational product\n             and/or presence of any non-healing wound, fracture, or ulcer.\n\n         10. Evidence of active bleeding or bleeding diathesis.\n\n         11. Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels that\n             increase the risk of pulmonary hemorrhage.\n\n         12. Recent hemoptysis.\n\n         13. Any serious and/or unstable pre-existing medical, psychiatric, or other condition\n             that could interfere with subject's safety, provision of informed consent, or\n             compliance to study procedures.\n\n         14. Unable or unwilling to discontinue use of prohibited medications listed in the\n             research protocol for at least 14 days or five half-lives of a drug (whichever is\n             longer) prior to the first dose of study drug and for the duration of the study.\n\n         15. Concurrent use of other substances known or likely to interfere with the\n             pharmacokinetics of pazopanib\n\n         16. Treatment with any of the following anti-cancer therapies: radiation therapy, surgery\n             or tumor embolization within 14 days prior to the first dose of pazopanib OR\n             chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal\n             therapy within 14 days or five half-lives of a drug (whichever is longer) prior to\n             the first dose of Pazopanib.\n\n         17. Administration of any non-oncologic investigational drug within 30 days or 5 half\n             lives whichever is longer prior to receiving the first dose of study treatment.\n\n         18. Any ongoing toxicity from prior anti-cancer therapy that is > Grade 1 and/or that is\n             progressing in severity, except alopecia.\n\n         19. For FDG-PET imaging part of the study:\n\n               -  uncontrolled diabetes mellitus\n\n               -  only evaluable tumors in brain or urinary tract, as these cannot be evaluated by\n                  FDG-PET scan."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with advanced soft tissue sarcoma who have an indication for pazopanib treatment."
            }
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01995981", 
            "org_study_id": "UMCN-ONCO-201303", 
            "secondary_id": "2013-003533-16"
        }, 
        "intervention": {
            "arm_group_label": "Advanced soft tissue sarcoma patients", 
            "intervention_name": "Pazopanib", 
            "intervention_type": "Drug", 
            "other_name": "Votrient"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Sarcoma, Soft Tissue", 
            "Pazopanib", 
            "Positron-Emission Tomography", 
            "Pharmacokinetics", 
            "Biomarker"
        ], 
        "lastchanged_date": "December 11, 2013", 
        "location": {
            "contact": {
                "email": "m.vlenterie@onco.umcn.nl", 
                "last_name": "Myrella Vlenterie, MD", 
                "phone": "0031243610353"
            }, 
            "facility": {
                "address": {
                    "city": "Nijmegen", 
                    "country": "Netherlands", 
                    "zip": "6525 GA"
                }, 
                "name": "Radboud University Nijmegen Medical Centre"
            }, 
            "investigator": [
                {
                    "last_name": "Winette van der Graaf, prof. PhD. MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Myrella Vlenterie, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_groups": "1", 
        "official_title": "Individualizing Pazopanib Therapy by exploRing the Role of Early Metabolic responsE and Drug Exposure as a preDICTor for Treatment Outcome in Patients With STS", 
        "overall_contact": {
            "email": "m.vlenterie@onco.umcn.nl", 
            "last_name": "Myrella Vlenterie, MD", 
            "phone": "0243610353"
        }, 
        "overall_official": [
            {
                "affiliation": "Radboud University", 
                "last_name": "Winette van der Graaf, prof. PhD. MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Radboud University", 
                "last_name": "Wim Oyen, prof. PhD. MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Radboud University", 
                "last_name": "Nielka van Erp, PharmD. PhD.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "FDG (18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose) uptake", 
                "safety_issue": "No", 
                "time_frame": "baseline, 2 weeks and 8 weeks after start treatment"
            }, 
            {
                "description": "This measurement is performed at 2 weeks and 8 weeks after start treatment", 
                "measure": "Pharmacokinetics (AUC)", 
                "safety_issue": "No", 
                "time_frame": "0, 1, 2, 3, 4, 6, 8, 10, 24 hours post-dose"
            }
        ], 
        "reference": {
            "PMID": "22595799", 
            "citation": "van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Sch\u00f6ffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P; EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012 May 19;379(9829):1879-86. Epub 2012 May 16."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01995981"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Adverse events (CTCAE v4.0)", 
            "safety_issue": "Yes", 
            "time_frame": "2 weeks and 8 weeks after start treatment"
        }, 
        "source": "Radboud University", 
        "sponsors": {
            "collaborator": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Radboud University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "September 2013"
    }
}